Abstract: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago, the United States, from May 31 to June 4 in 2024. In recent years, antibody-drug conjugates (ADCs) have become one of the most popular targeted therapies because of their high specificity, efficacy, and low toxicity, making them a focal point in this ASCO meeting. Currently, over 100 ADCs are under investigation, demonstrating the considerable development potential of ADCs in the field of targeted cancer therapy. The aforementioned conference reported several recent research advancements regarding ADCs for the treatment of breast cancer (BC). This review summarizes the latest progress of ADCs in BC treatment discussed at the conference.